Institute of Biochemistry and Cell Biology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
PLoS One. 2013 Aug 13;8(8):e73422. doi: 10.1371/journal.pone.0073422. eCollection 2013.
Minocycline, a second-generation tetracycline antibiotic, exhibits anti-inflammatory and neuroprotective effects in various experimental models of neurological diseases, such as stroke, Alzheimer's disease, amyotrophic lateral sclerosis and spinal cord injury. However, conflicting results have prompted a debate regarding the beneficial effects of minocycline.
In this study, we analyzed minocycline treatment in organotypic spinal cord cultures of neonatal rats as a model of motor neuron survival and regeneration after injury. Minocycline was administered in 2 different concentrations (10 and 100 µM) at various time points in culture and fixed after 1 week.
Prolonged minocycline administration decreased the survival of motor neurons in the organotypic cultures. This effect was strongly enhanced with higher concentrations of minocycline. High concentrations of minocycline reduced the number of DAPI-positive cell nuclei in organotypic cultures and simultaneously inhibited microglial activation. Astrocytes, which covered the surface of the control organotypic cultures, revealed a peripheral distribution after early minocycline treatment. Thus, we further analyzed the effects of 100 µM minocycline on the viability and migration ability of dispersed primary glial cell cultures. We found that minocycline reduced cell viability, delayed wound closure in a scratch migration assay and increased connexin 43 protein levels in these cultures.
The administration of high doses of minocycline was deleterious for motor neuron survival. In addition, it inhibited microglial activation and impaired glial viability and migration. These data suggest that especially high doses of minocycline might have undesired affects in treatment of spinal cord injury. Further experiments are required to determine the conditions for the safe clinical administration of minocycline in spinal cord injured patients.
米诺环素是一种第二代四环素类抗生素,在中风、阿尔茨海默病、肌萎缩侧索硬化和脊髓损伤等多种神经疾病的实验模型中具有抗炎和神经保护作用。然而,相互矛盾的结果引发了关于米诺环素的有益效果的争论。
在这项研究中,我们分析了米诺环素在新生大鼠器官型脊髓培养物中的治疗作用,作为损伤后运动神经元存活和再生的模型。米诺环素在培养物中的不同时间点以 2 种不同浓度(10 和 100µM)给药,并在 1 周后固定。
延长米诺环素给药时间会减少器官型培养物中运动神经元的存活。这种作用在较高浓度的米诺环素下得到了强烈增强。高浓度的米诺环素减少了器官型培养物中 DAPI 阳性细胞核的数量,并同时抑制了小胶质细胞的激活。覆盖对照器官型培养物表面的星形胶质细胞在早期米诺环素处理后呈现出外围分布。因此,我们进一步分析了 100µM 米诺环素对分散的原代神经胶质细胞培养物活力和迁移能力的影响。我们发现米诺环素降低了细胞活力,延迟了划痕迁移实验中的伤口闭合,并增加了这些培养物中连接蛋白 43 蛋白的水平。
高剂量米诺环素的给药对运动神经元的存活有害。此外,它抑制小胶质细胞的激活,并损害神经胶质细胞的活力和迁移。这些数据表明,特别是高剂量的米诺环素可能对脊髓损伤的治疗有不良影响。需要进一步的实验来确定米诺环素在脊髓损伤患者中的安全临床给药条件。